Answers are grounded in this paper and cite their sources.
Background & aims Previous studies showed combination treatment with short interfering RNA JNJ-73763989 (JNJ-3989)±capsid assembly modulator bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) was well tolerated by chronic hepatitis B (CHB) patients, with JNJ-3989 dose-dependent reductions in viral markers, including hepatitis B surface antigen (HBsAg). The open-label, single arm phase 2a PENGUIN study (NCT04667104) evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in virologically suppressed CHB patients. Methods Hepatitis B e antigen (HBeAg)-positive or -negative, virologically suppressed patients on NA were included; all received JNJ-3989±bersacapavir for 24 weeks (some did not start/discontinued bersacapavir due to protocol amendment) with PegIFN-α2a added during the final 12 weeks of treatment. Primary endpoint was the proportion of patients with ≥2log 10 IU/mL HBsAg reduction from baseline at Week 24 (W24). Safety, tolerability, and proportion of patients meeting predefined NA stopping criteria were assessed. After 24 weeks of treatment, NA was stopped when stopping criteria were met; all patients were followed for 48 weeks. Efficacy and safety endpoints were summarized using descriptive statistics. Results 48 patients (HBeAg-positive, n=11; HBeAg-negative, n=37) were enrolled; 47 reached Follow-up Week 48 (FUW48). 31/48 (64.6%) patients achieved the primary endpoint; 1 achieved HBsAg seroclearance (<0.05IU/mL) at W24 and FUW48 after stopping NA. Mean HBsAg changes from baseline were –1.43, –2.18, and –0.71log 10 IU/mL at W12, W24, and FUW48. At W24, 15/48 (31.3%) patients met NA stopping criteria; 11/15 (73.3%) remained off NA by FUW48. One patient achieved functional cure at FUW48. Adverse events were consistent with known PegIFN-α2a safety profile. Conclusions Treatment with JNJ-3989±bersacapavir+NA and PegIFN-α2a was generally well tolerated. Most patients had pronounced HBsAg reductions from baseline, no additional benefit from PegIFN-α2a, and did not achieve functional cure. ClinicalTrials.gov Identifier NCT04667104. Impact and implications Previous studies with JNJ-73763989 (JNJ-3989) ± bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NA) in patients with chronic hepatitis B (CHB) have demonstrated JNJ-3989 dose-dependent and robust reductions in viral markers; however, functional cure was only rarely achieved. The current study assessed whether the addition of pegylated interferon alpha-2a (PegIFN-α2a) to a JNJ-3989–based regimen after HBsAg levels were reduced would lead to further HBsAg declines and improved outcomes during off-treatment follow-up. Study results confirmed pronounced HBsAg reductions from baseline in virologically suppressed patients with HBeAg-positive or -negative CHB. However, the addition of PegIFN-α2a to JNJ-3989 ± bersacapavir and NA for the last 12 weeks of a 24-week treatment period did not seem to improve antiviral activity in the studied population. Studies in other CHB populations, including treatment-naïve, HBeAg-positive patients, may help elucidate whether this or other treatment regimens including JNJ-3989 and NA can lead to functional cure in a larger proportion of patients.
No takes yet. Share an insight, caveat, or question.
Gane et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: